US to resume Johnson & Johnson vaccinations despite rare clot risk

The FDA and CDC have confidence that this vaccine is effective in preventing COVID-19, said the statement

The US Food and Drug Administration (FDA) and the US Centres for Disease Control and Prevention (CDC) announced on Friday that they are determined to lift the pause regarding the use of the Johnson & Johnson COVID-19 vaccine, allowing its resumed use for adults.

The decision was made following a thorough safety review, including two meetings of the CDC’s Advisory Committee on Immunisation Practices (ACIP), said a joint statement. The pause was recommended on April 13 after reports of six cases of a rare and severe type of blood clot in individuals following administration of the Johnson & Johnson vaccine.

During the pause, the medical and scientific teams examined available data to assess the risk of thrombosis involving the cerebral venous sinuses, or CVST (large blood vessels in the brain), and other sites in the body along with thrombocytopenia, or low blood platelet counts, according to the statement. The teams at FDA and CDC also conducted extensive outreach to providers and clinicians to ensure they were made aware of the potential for these adverse events and could properly manage and recognise these events due to the unique treatment required for blood clots and low platelets. The FDA has determined that the available data shows that the vaccine’s known and potential benefits outweigh its known and potential risks.
AGENCIES

EU likely to vaccinate 70 per cent adults

European Commission President Ursula von der Leyen said the goal could be achieved by the end of July, instead of late September as had been previously predicted. She said her commission was close to concluding a deal with BioNTech and Pfizer to supply 1.8 billion additional vaccine doses.

‘New strain in SL more dangerous’

A new Coronavirus strain that is airborne and more potent than all those found previously in Sri Lanka, has been discovered in the island nation, according to a top immunologist in Colombo. The variant, which is highly transmissible, can remain airborne for nearly an hour and is spreading fast, Neelika Malavige, the head of the Department of Immunology and Molecular Sciences of the Sri Jayawardenapura University said.  Health authorities feared that the new variant is spreading rapidly after last week’s New Year celebrations with more younger people getting infected. “In the next two incubation periods, the disease can progress to a third wave,” Upul Rohana, of the Public Health Inspectors said.

14,63,47,752
TOTAL Number OF CORONAVIRUS

CASES IN THE WORLD

31,02,346
Number OF DEATHS WORLDWIDE 

12,41,69,612
Number OF RECOVERED PATIENTS

This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever

"Exciting news! Mid-day is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest news!" Click here!